Michael Schirm, Ph.D

Director of the R&D Proteomics Group CellCarta

Mass Spectrometry-Based Clinical Proteomics: Applications in Cancer Research

Abstract

Mass spectrometry (MS) is a highly sensitive, specific and powerful analytical technology with broad applications and benefits for clinical sample analysis. Three case studies using mass-spectrometry based proteomics will be presented.

Case Study 1 will focus on the use of intact mass analysis to measure Minimal Residual Disease (MRD) in patients with multiple myeloma (MM). The intact mass analysis approach seems to be significantly more sensitive than other analytical platforms (e.g., multiparametric flow cytometry, next-generation sequencing, etc.) and may prove more effective for monitoring treatment efficacy.

Case Study 2 will focus on the development and analytical validation of an immunoprecipitation (IP) LC-MRM based method for quantitation of a bispecific antibody based drug product and its metabolites in plasma samples from a Phase 1 clinical study.

Case Study 3 will showcase the highly multiplexed measurement of immunomodulatory proteins using peptide-IP LC-MRM to support immunotherapy trials. Data will be presented showing the reliable and accurate measurement of up to 113 immunomodulatory proteins in human plasma and cell lines.

Biosketch

Michael Schirm is the Director of the R&D Proteomics Group at CellCarta, a global CRO providing a broad range of biomarker platforms and services to the biopharmaceutical industry. Michael obtained a Diploma in Chemical Engineering from the University of Applied Sciences Munster, Germany, before pursuing a Ph.D. in Analytical Chemistry at the University of Montreal under the supervision of Drs. Karen Waldron and Pierre Thibault. Upon receiving his doctorate, Michael joined Caprion Biosciences, in Montreal (known later as Caprion-HistoGeneX, and now rebranded as CellCarta). As the Director of the R&D Proteomics Group, Michael oversees a dedicated group of scientists responsible for the development and analytical validation of highly specialized, custom mass-spectrometry based methods for protein, peptide and PTM quantitation in complex biological matrices; these specialized assays are then deployed for the analysis of client samples in support of discovery, translational and clinical studies.

Date
Date(s) - January 18, 2024
6:00 pm - 8:30 pm

Emplacement / Location
Université de Montréal - Campus MIL (Beer and pizza at 18h, conference at 19h in A-4502)